



Attorney Docket No. 045636-5039

#8
Election
7/17/02
PATENT

RECEIVED

In re Application of:

Lise THIBODEAU et al.

Application No.: 09/632,806

Filed: August 4, 2000

For: USE OF HIV-1 gp120 AND gp160 PROTEINS
MODIFIED IN THE V3 LOOP FOR THE
PREPARATION OF VACCINE COMPOSITIONS
AND FORMULATIONS CONTAINING THE SAME

Group Art Unit: 1648

Examiner: J. Parkin

JUL 15 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO ELECTION REQUIREMENT

In response to the Election Requirement dated June 12, 2002 (Paper No. 7), the period for reply to which extends through July 12, 2002, Applicants hereby elect with traverse the invention identified in the Office Action as Group III, claims 15-20, drawn to a vaccine composition comprising a recombinant envelope protein, pharmaceutically acceptable vehicle, adjuvant and liposomes. An action on the merits is requested.

Applicants believe that no fees are required with this filing, however, except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

F. Pierre Vanderkest; Reg. No. 49,088

for Michael S. Tuscan, Ph.D.

Reg. No. 43,210

July 12, 2002

CUSTOMER NO. 009629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Ave., N.W.
Washington, DC 20004
202.739.3000 (voice)
202.739.3001 (fax)

1-WA/1829351.1